Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., . . . Lonial, S. (2017). Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res.
シカゴスタイル引用形Vogl, Dan T., et al. "Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination With Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma." Clin Cancer Res 2017.
MLA引用形式Vogl, Dan T., et al. "Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination With Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma." Clin Cancer Res 2017.
警告: この引用は必ずしも正確ではありません.